FANCA (D1L2Z) Rabbit mAb #14657
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 160 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Protocol
Specificity / Sensitivity
FANCA (D1L2Z) Rabbit mAb recognizes endogenous levels of total FANCA protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala514 of human FANCA protein.
Background
Fanconi anemia (FA) is an autosomal recessive genetic disorder that results in chromosomal breakage, bone marrow failure, hypersensitivity to DNA cross-linking agents (such as mitomycin C), and a predisposition to cancer (1). The ubiquitously expressed FA complementation group A protein (FANCA, FAA) is a component of the FA nuclear complex that also contains FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM. In response to DNA damage, the FA nuclear complex induces mono-ubiquitination of FANCD2 and FANCI (2). FANCJ/BRIP1, FANCD1/BRCA2 and FANCN/PALB2 are then recruited to sites of DNA damage along with other DNA repair proteins. FA signaling is important in maintenance of chromosome stability and control of mitosis (3).
DNA-damage-dependent localization and stability of FANCA protein regulates FA complex function and localization. Interaction between FANCA protein and the Hsp90 chaperone protein regulates FANCA protein stability and turnover, and may play a role in controlling the FA DNA damage pathway (4). Mutations in the corresponding FANCA gene are responsible for the majority of cases of Fanconi anemia (5).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.